Biopharma

TXI is dedicated to overcoming the obstacles that hinder scientists from accessing and leveraging data effectively. In biopharma, vast amounts of data are often siloed and compartmentalized, making it challenging to integrate with external data, such as real-world data (RWD), or even across internal data sets. This fragmentation poses a significant obstacle to accelerating the development of novel treatments, perpetuating the industry's current norm of taking ten years and costing over $2 billion.

To unleash the potential of data in biopharma, researchers need seamless access to data, and they must adopt a more data-driven approach to their work. This transformation isn’t just about wrangling data or building new tools. It requires biopharmas to embrace digitalization fully, involving people, culture, platforms, and, of course, data, across every aspect of the organization.

By partnering with TXI to address data fragmentation and silos that hinder scientific breakthroughs, biopharmas can accelerate the development of novel treatments and ultimately bring them to patients faster and more efficiently.

At TXI, we recognize that access to real-world patient data, particularly longitudinal clinico-genomic data, is paramount for biopharmaceutical companies. Unfortunately, existing sources often provide only a narrow window into patients. Clinical trials cover only a small set of patients with a very specific set of questions. Real World Data (RWD) can provide a more longitudinal view of patients, but typically lacks depth.

TXI's digital solutions address this issue by helping biopharmaceuticals create direct relationships with patients, allowing patients to participate as collaborative partners in ongoing research. By doing so, biopharmas can obtain a 360° view of their patients' health conditions and goals, gaining a more comprehensive understanding of the patient experience. Patients, in turn, can have early access to cutting-edge research and can take part in observational and clinical studies, potentially improving their own outcomes.

By partnering with TXI, biopharmaceutical companies can accelerate their research and development efforts and bring innovative treatments to patients faster.

Clinical trials represent the longest and most expensive phase of drug discovery and development. It is essential to accurately forecast trial duration and select the right countries and sites. Mistakes may lead to inefficient investment decisions, delays or even unnecessary failures. Unfortunately, forecasting and site selection often rely more on study managers' experience rather than the abundance of data available today.

At TXI, we specialize in creating data-driven solutions for experts such as study managers. With a TXI solution, a study manager can quickly generate enrollment curves for multiple scenarios based on historical data. They can dial in the right balance of speed vs constraints when selecting countries and sites. This information can then inform leadership's portfolio decisions, enable operational tracking, and facilitate ongoing adjustments to ensure the trial's success.

TXI provides cutting-edge digital solutions that enable medical research to be conducted at scale. By harnessing advanced data analytics, machine learning, and AI technologies, we help biopharmaceutical companies and research institutions extract insights from large and complex datasets that were previously inaccessible.

Our deep expertise in data management, software development, and cloud-based technologies allows for the seamless integration of diverse data sources and the creation of powerful data-driven tools. These tools empower researchers to analyze and interpret data more efficiently, accelerating the discovery of new treatments and improving patient outcomes. With TXI's support, medical research can be conducted at scale, facilitating breakthroughs in biopharmaceuticals and healthcare that have the potential to transform lives.